Eli Lilly and Company

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +45

The One Thing To Settle Before Buying Eli Lilly Stock

Drug pricing Earnings report Financial outlook AI-generated analysis

πŸ“ˆ Eli Lilly's U.S. revenue surged 34% in Q3 2026, reaching new highs driven by massive volume increases in Mounjaro and Zepbound sales.

πŸ’° Despite the revenue boom, the net price per prescription for Lilly's U.S. sales fell 10% in the third quarter of 2026.

🌍 Global revenue hit $24.4 billion in Q3 2026, with Mounjaro and Zepbound contributing over $16 billion to the total.

πŸ“… Management raised its full-year 2026 revenue forecast to $91.5 billion at the midpoint, up from the previous $86 billion estimate.

πŸ₯ The company expects a shift in U.S. patient mix toward Medicare and Medicaid in 2027, which typically carries lower net prices per prescription.

πŸ’Έ Approximately $900 million of Q3 revenue was generated by milestone payments and adjustments to rebate estimates across all markets.

πŸ“‰ Management aims for a tighter pricing band for obesity drugs globally compared to other pharmaceutical categories.

πŸ” Investors are advised to watch the February 2027 earnings report for specific data on Q4 U.S. price changes versus volume growth.

πŸš€ The two weight-loss drugs now account for the majority of Lilly's revenue, making them critical to the company's financial health.

Bullish Signals
  • Eli Lilly achieved a 34% year-over-year increase in U.S. revenue during the third quarter of 2026, demonstrating strong demand for its core products.
  • The company generated over $16 billion in revenue from Mounjaro and Zepbound combined in Q3 2026, highlighting the massive scale of its weight-loss franchise.
  • Management raised its full-year 2026 revenue forecast to $91.5 billion at the midpoint, reflecting confidence in continued growth despite pricing headwinds.
  • The company secured approximately $900 million in additional revenue from milestone payments and rebate adjustments during the third quarter of 2026.
Risk Factors
  • Eli Lilly's net price per prescription in the U.S. declined by 10% in the third quarter of 2026, indicating ongoing pricing pressure on its blockbuster drugs.
  • The company anticipates a shift in U.S. patient mix toward Medicare and Medicaid in 2027, which management acknowledges will bring lower net prices per prescription compared to commercial insurance.
Full Analysis
Eli Lilly (LLY) reported a 34% increase in U.S. revenue for the third quarter of 2026, driven primarily by surging volumes of its weight-loss drugs Mounjaro and Zepbound. Despite this volume growth, the company's net price per prescription in the U.S. declined by 10% during the same period. Management noted that while the balance between pricing power and sales volume remains a key metric to monitor, the overall revenue expansion was bolstered by approximately $900 million in milestone payments and adjustments to rebate estimates. Global revenue for Eli Lilly reached $24.4 billion in the third quarter of 2026, representing a 38.6% year-over-year increase. The two blockbuster drugs, Mounjaro and Zepbound, accounted for over $16 billion of total revenue, supplying roughly $6 billion of the quarterly growth. Consequently, these two products constitute the vast majority of the company's financial performance, meaning any sustained shift in pricing or reimbursement rates will have a disproportionate impact on overall earnings. Looking ahead to 2027, management expects commercial insurance coverage in the U.S. to remain stable while new access expands into Medicare and Medicaid markets. The company anticipates that lower net prices associated with these government programs will be offset by higher prescription volumes rather than representing an overall price cut. Additionally, the 2026 revenue forecast was raised to $91.5 billion at the midpoint, excluding about $2 billion in one-time items related to milestone payments and rebate adjustments. Analysts are closely watching the upcoming fourth-quarter report expected in February 2027 to determine the specific magnitude of U.S. price declines versus volume growth. Management has stated its goal is to maintain a tighter pricing band for obesity drugs globally compared to other therapeutic categories. Investors will need to track whether the shift toward lower-paying government payers materially impacts margins or if volume expansion continues to drive top-line success.